Alternative site of implantation affects tumor malignancy and metastatic potential in mice: Its comparison to the flank model

Cancer Biology and Therapy

Volumn 8, Issue 4, 2009, Pages 375-379

  Speroni, Lucia ^a   Bustuoabad, Victoria De Los Angeles ^b   Gasparri, Julieta ^a   Chiaramoni, Nadia Silvia ^a   Taira, María Cristina ^a   Ruggiero, Raúl Alejandro ^c   Alonso, Silvia Del Valle ^a  

^a UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

^b Instituto de la Vision Ciudad Autonoma de Buenos Aires   (Argentina)

^c INST DE INVEST HEMATOLOGICAS   (Argentina)

Author keywords

Cellular influx; Dorsal region of foot; Immune reaction; Tumor model in mice

Indexed keywords

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CANCER TRANSPLANTATION; CONTROLLED STUDY; FIBROSARCOMA; HISTOLOGY; INNATE IMMUNITY; LUNG METASTASIS; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS; MICROENVIRONMENT; MOUSE; NONHUMAN; PHENOTYPE; SURVIVAL RATE; TUMOR GROWTH; TUMOR MODEL;

EID: 62549147557     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.4.7452     Document Type: Article

References (28)

1. Hirst GL, Balmain A. Forty years of cancer modeling in the mouse. Eur J Cancer 2004; 40:1974-80.
2. Vitale S, Cambien B, Karimdjee BF, Barthel R, Staccini P, Luci C, et al. Tissue-specific differential antitumour effect of molecular forms of fractalkine in a mouse model of metastatic colon cancer. Gut 2007; 56:365-72.
3. Ek ET, Dass CR, Choong PF. Commonly used mouse models of osteosarcoma. Crit Rev Oncol Hematol 2006; 60:1-8.
4. Hendrix MJC, Seftor EA, Seftor REB, Kasemeier-Kulesa J, Kulesa PM, Postovit LM. Reprogramming metastatic tumor cells with embryonic microenvironments. Nature 2007; 7:246-55.
5. Seftor EA, Meltzer PS, Kirschmann DA, Margaryan NV, Seftor REB, Hendrix MJC. The epigenetic reprogramming of poorly aggressive melanoma cells by a metastatic microenvironment. J Cell Mol Med 2006; 10:174-96.
6. Maffini MV, Soto AM, Calabro JM, Ucci AA, Sonnenschein C. The stroma as a crucial target in rat mammary gland carcinogenesis. J Cell Science 2004; 117:1287-90.
7. Barrera CN, Mazzolli AB, Bustuoabad OD, Andreetta AM, Pasqualini CD. Macrophages and tumor growth II. Cell kinetics at the site of allogeneic tumor growth. Cancer Invest 1985; 3:7-13.
8. Illmensee K, Mintz B. Totipotency and normal differentiation of a single teratocarcinoma cell cloned by injection into blastocysts. Proc Natl Acad Sci USA 1976; 549-53.
9. Kulesa PM, Kasemeier-Kulesa JC, Teddy JM, Margaryan NV, Seftor EA, Seftor REB, et al. Reprogramming metastatic melanoma cells to assume a neural crest cell-like phenotype in an embryonic microenvironment. PNAS 2006; 103:3752-7.
10. Crnalic S, Häkansson I, Boquist L, Löfvenberg R, Brostrom LA. A novel spontaneous metastasis model of human osteosarcoma developed using orthotopic transplantation of intact tumor tissue into tibia of nude mice. Clin Exp Metastasis 1997; 15:164-72.
11. Luu HH, Kang Q, Park JK, Si W, Luo Q, Jiang W, et al. An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin Exp Metastasis 2005; 22:319-29.
12. Phren RT. Immunostimulation and Immunoinhibition of Premalignant Lesions. Theor Bio Med Model 2007; 4:6.
13. Kaliss N. Immunological enhancement and inhibition of tumor growth: Relationship to various immunological mechanisms. Federation Proc 1965; 24:1024-9.
14. Okada F, Kawaguchi T, Habelhah H, Kobayashi T, Tazawa H, Takeichi N, et al. Conversion of human colonic adenoma cells to adenocarcinoma cells through inflammation in nude mice. Lab Invest 2000; 80:1617-28.
15. Mueller MM, Fusenig NE. Tumor -s troma interactions directing phenotype and progression of epithelial skin tumor cells. Differentiation 2002; 70:486-97.
16. Kenny PA and Bissell MJ. Tumor reversion: Correction of malignant behavior by microenvironmental cues. Int J Cancer 2003; 107:688-95.
17. Maffini MV, Calabro JM, Soto AM, Sonnenschein C. Stromal regultaion of neoplastic development: Age-dependent normalisation of neoplastic mammary cells by mammary stroma. Am J Pathol 2005; 167:1405-10.
18. Franco M, Bustuoabad OD, Di Gianni PD, Goldman A, Pasqualini CD, Ruggiero RA. A serum-mediated mechanism for concomitant resistance shared by immunogenic and non-immunogenic murine tumours. Br J Cancer 1996; 74:178-86.
19. Di Gianni P, Minnucci FS, Alves Rosa MF, Vulcano M, Isturiz MA. Anti-oxidants inhibit the enhancement of the immune response caused by oil adjuvants. Scand J Immunol 1996; 43:413-20.
20. Attia MA, Weiss DW. Immunology of spontaneous mammary carcinomas in mice V. Acquired tumor resistance and enhancement in strain-A mice infected with mammary tumor virus. Cancer Res 1966; 26:1787-800.
21. Mekid H, Tounekti O, Spatz A, Cemazar M, El Kebir FZ, Mir LM. In vivo evolution of tumour cells after the generation of double-strand DNA breaks. Br J Cancer 2003; 88:1763-71.
22. Buhtoiarov IN, Sondel PM, Eickhoff JC, Rakhmilevich AL. Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides. Immunology 2007; 120:412-23.
23. Bustuoabad OD, Ruggiero RA, di Gianni P, Lombardi MG, Belli C, Camerano GV, et al. Tumor transition zone: A putative new morphological and functional hallmark of tumor aggressiveness. Oncol Res 2005; 15:169-82.
24. Coussens LM and Werb Z. Inflammation and cancer. Nature 2002; 420:860-7.
25. Aldaz CM, Conti CJ, Gimenez IB, Slaga TJ, Klein-Szanto AJP. Cutaneous changes during prolonged application of 12-O-Tetradecanoylphorbol-13-acetate on mouse skin and residual effects after cessation of treatment. Cancer Res 1985; 45:2753-9.
26. Tew JG, Mandel TE and Rice PL. Immune elimination and immune retention: the relationship between antigen retained in the foot and the elicitation of footpad swelling. Immunol 1980; 40:425-33.
27. Huvos AG, Heilweil M, Bretsky SS. The pathology of malignant fibrous histiocytoma of bone. A study of 130 patients. Am J Surg Pathol 1985; 9:853-71.
28. Jeejeebhoy HF. Stimulation of tumor growth by the immune response. Int J Cancer 1974; 13:665-78.